24 September 2008 ENLIGHT, ESF Workshop-Oxford European Network for Light Ion Therapy ENLIGHT Manjit Dosanjh ENLIGHT Coordinator & CERN.

Slides:



Advertisements
Similar presentations
MedAustron – Austrian Hadron Therapy Centre
Advertisements

GEANT4 simulation of an ocular proton beam & benchmark against MC codes D. R. Shipley, H. Palmans, C. Baker, A. Kacperek Monte Carlo 2005 Topical Meeting.
Energy deposition and neutron background studies for a low energy proton therapy facility Roxana Rata*, Roger Barlow* * International Institute for Accelerator.
Knowledge Manjit Dosanjh Knowledge Transfer SKF, Rabat, 11 May 2013.
Some remaining questions in particle therapy radiation biology Bleddyn Jones University of Oxford 1. Gray Institute for Radiation Oncology & Biology 2.
Radiation Therapy (RT). What is cancer? Failure of the mechanisms that control growth and proliferation of the cells Uncontrolled (often rapid) growth.
Tumour Therapy with Particle Beams Claus Grupen University of Siegen, Germany [physics/ ] Phy 224B Chapter 20: Applications of Nuclear Physics 24.
Study of the fragmentation of Carbon ions for medical applications Protons (hadrons in general) especially suitable for deep-sited tumors (brain, neck.
Knowledge Transfer | Accelerating Innovation G. Anelli, Giovanni Anelli Knowledge Transfer Group Leader CERN.
Mid Term Review Meeting, 26 September 2012S. GIRON1 * The research project has been supported by a Marie Curie Early Initial Training Network Fellowship.
15 April Fostering Entrepreneurship among young people through education: a EU perspective Simone Baldassarri Unit “Entrepreneurship” Forum “Delivering.
PAMELA Contact Author: CONFORM is an RCUK-funded Basic Technology Programme PAMELA: Concepts Particle Accelerator for MEdicaL Applications K.Peach(JAI,
WP4: Applications of Accelerators
Heavy Ion Tumor Therapy
Report from WP4: Applications of Accelerators AccApplic  Accelerator Applications  Aims of WP4  Workshops so far  Future workshops  Status  Plans.
Using CERN Technologies for Medical Applications Steve Myers Director of Accelerators and Technology, Geneva, Switzerland 12th June 2013, 1.
TRANSCAN ERA-NET on translational Cancer Research Application for funds TRANSCAN ERA-NET on translational Cancer Research Aims:  Impact of the health.
The Skandion clinic, plans for the use of particle beams for radiation therapy in Sweden presented by Erik Grusell, medical radiation physicist Dept of.
1 GEANT4: Applications in Medical Physics B. Caccia Department of Technology and Health Istituto Superiore di Sanità (Italian National Institute of Health)
TREATMENT PLANNING Modelling chemo-hadron therapy Lara Barazzuol | Valencia | 19 June 2009.
Milestones M5 and M6 Mid-Term Review, October 2013M. Silari – ARDENT overview1 M5: comparison of detector technologies (WP1) M6: choice of detector technology.
08 November 2006ENLIGHT++ for KnowARC project1 ENLIGHT ++ Proton and Ion Therapy “e”-infrastructure for health; “e” for “enhanced, enabled, excellent”
1 WERT: WP 5 RG EVANS ASSOCIATES November 2010 Aim To pilot and evaluate the content and context of the course material with target groups To help women.
M. Silari - The ARDENT ITN project 1EURADOS, Vienna, 7-10 February 2012 ARDENT February 2012 – January 2016 Advanced Radiation Dosimetry European Network.
Response of the sensors to different doses from tests in Israel Radiotherapy is used as a treatment in around 50% of cancer cases in the UK. Predominantly,
From Physics to Health applications: challenges and benefits Serbia Detector School, 13 September 2014 Manjit Dosanjh, CERN.
Wolfgang Enghardt Technische Universität Dresden, Germany OncoRay – Center for Radiation Research in Oncology and Forschungszentrum Dresden-Rossendorf,
ENLIGHT Meeting Novel Imaging Systems WP1: Time-of-flight in-beam PET (TERA, INFN, IFIC/CSIC, IN2P3, OncoRay, CERN, PoliAnnecy, Oxford) WP2: In-beam single.
ENLIGHT- PARTNER Meeting, June 2009, IFIC- Valencia Manjit DOSANJH ENLIGHT Coordinator & CERN.
Cancer Therapy and Imaging Cancer Therapy and Imaging Rob Edgecock STFC Rutherford Appleton Laboratory.
CERN Medical Applications Steve Myers Head of CERN Medical Applications Former Director of Accelerators and Technology CERN, Geneva.
The European Innovation Partnership for asthma: an opportunity for change Samantha Walker PhD, Asthma UK Project Coordinator, EARIP (European Asthma Research.
The European agenda on improving the efficiency of employment and social policies: Bratislava, December 2011 The example of social experimentation.
Knowledge Transfer | Accelerating Innovation Turkey – CERN Industry Day, , D. Mazur David Mazur IP Dissemination Section Leader Knowledge Transfer.
ARDENT Advanced Radiation Dosimetry European Network Training initiative WP1: Gas Detectors S. Rollet.
October 16thPicosecond Lyon1 INNOTEP Project Using HEP technologies to improve TEP imaging: Development of innovative schemes for front-end electronic,
1 Radiotherapy, hadrontherapy and treatment planning systems. Faiza Bourhaleb INFN-Torino University Med 1er-Morocco  Radiotherapy  Optimization techniques.
March 2011 CERN, Geneva European Training Network for Particle Therapy Founded by the European Commission PARTNER.
Physics of carbon ions and principles of beam scanning G. Kraft Biophysik, GSI, Darmstadt, Germany PTCOG43 Educational Satellite Meeting: Principles of.
TPS & Simulations within PARTNER D. Bertrand, D. Prieels Valencia, SPAIN 19 JUNE 2009.
Cern.ch/knowledgetransfer. Knowledge Transfer | Accelerating Innovation Giovanni Anelli, CERN KT Training,
Present & Future of Accelerators for Hadrontherapy A. Faus-Golfe IFIC-IFIMED June 20091IFIMED'09 Symposium.
CERN in everyday life H F Hoffmann CERN honorary 1 CERN technologies in daily life H. F. Hoffmann/CERN honorary Globally networked science Competent.
PS losses during CT extraction, a history about 30 year long... J. Barranco, S. Gilardoni CERN - AB/ABP.
New Gantry Idea for H + /C 6+ Therapy G H Rees, ASTeC, RAL 4 th September, 2008.
Cern.ch/knowledgetransfer. Knowledge Transfer | Accelerating Innovation BE-KT Innovation Day,
ENLIGHT,12/2/20021 Health and Science, can CERN contribute? The Mission of CERN (1954): “The Organization shall provide for collaboration among European.
Comparison of MC and TP Dosimetry Simulations for Cancer Treatment Raymond Mumme May 12, 2014 Supervisor: Thiago Lima (PhD student) Head Supervisor: Dr.
Welcome! Rob Edgecock University of Huddersfield, UK  EuCARD2  WP4: Applications of Accelerators  This workshop  A few practical details EuCARD-2 is.
T. Fleck, GSI, Darmstadt, Germany ICALEPCS Status of the Control System for HICAT at an advanced stage of Commissioning Functions, Restrictions.
EuCARD-2 is co-funded by the partners and the European Commission under Capacities 7th Framework Programme, Grant Agreement EuCARD-2, ADS, linacs,
25-September-2005 Manjit Dosanjh Welcome to CERN International Workshop on African Research & Education Networking September ITU, UNU and CERN.
Ghislain Roy presenting work of C. Carli, A. Garonna, D. Abler D. Kuchler, V. Toivanen, S. Myers, M. Dosanjh, S. Schuh, A. Garcia Torrico, and many others.
Pushing the space charge limit in the CERN LHC injectors H. Bartosik for the CERN space charge team with contributions from S. Gilardoni, A. Huschauer,
Hartmut Eickhoff, GSI 1 Developments in Hadrontherapy -the role of Basic Research Institutes H. Eickhoff GSI/Darmstadt.
WP4: Applications of Accelerators AccApplic  WP4: Applications of Accelerators  The applications  Current workshops  Future workshops  Plans EuCARD-2.
The Australian Hadron Therapy and Research Facility.
HADRONTHERAPY IN ROMANIA NICOLAE IOAN VERGA M.D., Ph.D., D.Sc. “CAROL DAVILA” UNIVERSITY OF MEDICINE AND PHARMACY, ROMANIAN SOCIETY OF HADRONTHERAPY BUCHAREST,
April 17, Dejan TrbojevicFFAG07 -Non-Scaling FFAG gantries1 Non-Scaling FFAG Gantries Introduction: Motives: The most challenging problem in the carbon/proton.
European Organization for Nuclear Research
Knowledge Transfer at CERN
European-Comparative Effectiveness Research on online Depression Treatment E-COMPARED is funded by the European Community’s Seventh Framework.
European LEADER Association for Rural Development
BEAT_PRO Beam Tailoring and procedures optimization for clinical bnct
Extending intracranial treatment options with Leksell Gamma Knife® Icon™ Key Statements from Customer Perspective by University Medical Centre Mannheim.
EURADOS Working Group 9: Radiation Dosimetry in Radiotherapy
Accelerator layout > 1000 components (almost 300 magnets and power converters, 153 beam diagnostic devices, about 400m of vacuum pipes, a not neglectable.
Design of a PET-isotope-based hadron therapy facility
Figure 6 Double opposed-field irradiation of an idealized geometry
Giulio Magrin, TERA Foundation, Manjit Dosanjh, ENLIGHT++, CERN
Presentation transcript:

24 September 2008 ENLIGHT, ESF Workshop-Oxford European Network for Light Ion Therapy ENLIGHT Manjit Dosanjh ENLIGHT Coordinator & CERN

24 September 2008 ENLIGHT, ESF Workshop-Oxford Hadron therapy history … Today 51,000 patients (44,000 protons, 2900 carbon ions). …in ,000 patients since the beginning (18,300 protons) 1954Berkeley First patient

24 September 2008 ENLIGHT, ESF Workshop-Oxford Numbers of potential patients From studies in Austria, France, Germany and Italy X-ray therapy every 10 million inhabitants 20,000 pts/year Proton therapy 12% of X-ray patients 2,400 pts/year Therapy with Carbon ions for radio-resistant tumour 3% of X-ray patients 600 pts/year TOTAL for hadron therapy for 10 M 3,000 pts/year

24 September 2008 ENLIGHT, ESF Workshop-Oxford PIMMS at CERN in CERN–TERA–MedAustron Collaboration for optimized medical synchrotron CERN–TERA–MedAustron Collaboration for optimized medical synchrotron and protons linacs for carbon ions p p C C p RF cavity Resonance sextupole Betatron core Injection septum Electrostatic septum Extraction septum Sextupole horiz. chromaticity Sextupole vert. chromaticity Sextupole vert. chromaticity Sextupole horiz. chromaticity Circumference C = m Tune horizontal Q x = 1.67 Tune vertical Q z = MeV/u synchrotron 16 Bending Magnets 3 extraction systems: betatron core 1/3 resonance RF knock-out

24 September 2008 ENLIGHT, ESF Workshop-Oxford Why collaborate? Hadrontherapy to improve cancer treatment & outcome Very complex in all aspects of undertaking, therefore –Create common multidisciplinary platform –Share knowledge –Share best practices –Harmonise data –Provide training, education –Identify challenges –  innovate

24 September 2008 ENLIGHT, ESF Workshop-Oxford ENLIGHT challenges A heterogeneous group - different disciplines plus networking How to balance between basic research and the clinical needs? Many partners. How to give space to each and make progress with the main objectives? How to strike a balance between agenda of the single centres and the common ENLIGHT goals? Can we show ion therapy is more effective? Will practice validate the theory?

24 September 2008 ENLIGHT, ESF Workshop-Oxford ENLIGHT++ ingredients Clinical Studies Radiobiology Treatment planning for Intensity Modulated Particle Therapy Adaptive ion therapy and treating of moving organs Novel in-beam PET systems Feasibility study for innovative gantry designs Information and Communication Technologies for Hadron therapy –………..Future acclerator designs?? + networking

24 September 2008 ENLIGHT, ESF Workshop-Oxford What happened? ENLIGHT was established in 2002 ENLIGHT was composed of: Centres in Heidelberg, Lyon, and Pavia, CERN, EORTC, ESTRO, GSI, Karolinska, MedAustron, TERA, Czech Rep, Spain Main achievements: Creation of a European Hadrontherapy Community Common multidisciplinary platform with a shared vision Catalysed the transition from research to the clinical environment, 5 centres approved in Europe Served as a vehicle for education and dissemination

24 September 2008 ENLIGHT, ESF Workshop-Oxford European situation in 2008 The first two dual Carbon/proton centres in Heidelberg and Pavia are foreseen to start operation in 2008/9…..The first two dual Carbon/proton centres in Heidelberg and Pavia are foreseen to start operation in 2008/9….. Approved: Marburg (Germany), Etoile (France), MedAustron (Austria) and ARCHADE (France)Approved: Marburg (Germany), Etoile (France), MedAustron (Austria) and ARCHADE (France) Sweden, Belgium, Netherlands, Spain, UK ………Sweden, Belgium, Netherlands, Spain, UK ……… Clear desire for continuing the network focusing on new and on un- completed research topics and helping new initiatives….

24 September 2008 ENLIGHT, ESF Workshop-Oxford From ENLIGHT… to ENLIGHT++ In 2006 ENLIGHT++: + one “plus” for more hadrons (specifically protons), ++ the second “plus” refers to more Countries (17 countries, with >60 Institutions) ENLIGHT++ goes beyond being a network: Main Objective: Being more INCLUSIVE and becoming a RESEARCH network

24 September 2008 ENLIGHT, ESF Workshop-Oxford ENLIGHT 2008 European Commission funding project (Framework programme 7) Training 25 young researchers million euro project Research in optimizing 8.5 million euro project

25 researcher positions 21 PhDs and 4 Post-doc Positions posted: Will start 1st October 2008 PARTNER

Infrastructure project (8.5M Euros) 3 Pillars:Transnational access, Research and Networking Start at the beginning of 2009 ULICE

24 September 2008 ENLIGHT, ESF Workshop-Oxford Manjit Dosanjh HEALTH : Novel imaging systems for in vivo monitoring and quality control during tumour ion beam therapy. Single stage application. Collaborative project (small or medium-scale focused research project) The focus should be to develop novel imaging instruments, methods and tools for monitoring, in vivo and preferably in real time, the 3-dimensional distribution of the radiation dose effectively delivered within the patient during ion beam therapy of cancer. The ions should be protons or heavier ions. The system should typically be able to quantify the radiation dose delivered, to determine the agreement between the planned target volume and the actually irradiated volume, and for decreasing localisation uncertainties between planned and effective positions (e.g. of tissues or organs), and between planned and effective dose distribution during irradiation. It should aim at improving quality assurance, increasing target site (tumour) to normal tissue dose ratio and better sparing normal tissue.

24 September 2008 ENLIGHT, ESF Workshop-Oxford In-beam PET allows for a control of tumour irradiations by means of ion beams an in-vivo measurement of the ion range the validation of the physical model of the treatment planning the evaluation of the whole physical process of the treatment from planning to the dose application deviations between planned and actually applied dose distributions 1. What do we have? In-beam PET Advantages

24 September 2008 ENLIGHT, ESF Workshop-Oxford PET is not applicable to - real time monitoring: ▪ too slow ▪ T 1/2 ( 15 O) = 2 min, T 1/2 ( 11 C) = 20 min ▪ dose specific activity: ~ Bq cm -3 Gy -1 - quantitative imaging, precise dose quantification, feedback to treatment planning and to IGRT ▪ limited angle artefacts ▪ degradation of activity distributions by the metabolism ▪ degradation of activity distributions by moving organs ▪ inaccurate prediction of activity distributions from treatment planning due to unknown nuclear reaction cross sections 2. What do we have? In-beam PET Disadvantages and open problems

24 September 2008 ENLIGHT, ESF Workshop-Oxford 3. What do we need? Aim of this FP7-project - Development and proof of principle new solutions for ▪ non-invasive, real-time, in-vivo monitoring ▪ quantitative imaging ▪ precise dose quantification ▪ feedback to treatment planning ▪ real-time feedback to IGRT for moving organs - Preserve the leading European position in the field

24 September 2008 ENLIGHT, ESF Workshop-Oxford ENLIGHT Meeting Novel Imaging Systems WP1: Time-of-flight in-beam PET (F. Sauli, M. Rafecas) WP2: In-beam single particle tomography (W. Enghardt, D. Dauvergne) WP3: PT in-vivo dosimetry and moving target volumes (K. Parodi, G. Baroni) WP4: The combination of in-vivo dosimetry, treatment planning, and clinical relevance (D. Georg, B. Jones) WP5: Monte Carlo Simulation of in-vivo dosimetry (I. Buvat?, G. Battistoni)

24 September 2008 ENLIGHT, ESF Workshop-Oxford ENLIGHT Meeting Novel Imaging Systems WP1: Time-of-flight in-beam PET (TERA, INFN, IFIC/CSIC, IN2P3, OncoRay, CERN, PoliAnnecy, Oxford) WP2: In-beam single particle tomography (TERA, IBA, ICX, IFIC/CSIC, In2P3,Etoile,OncoRay) WP3: PT in-vivo dosimetry and moving target volumes (GSI, HIT, Oncoray, PoliMilano, Oxford, IBA, Etoile, IFIC/CSIC, INFN,TERA, Siemens?, Marburg?) WP4: The combination of in-vivo dosimetry, treatment planning, and clinical relevance (BHTC, MUVienna, Oxford, INFN, Siemens, Etoile, Marburg) WP5: Monte Carlo Simulation of in-vivo dosimetry (CERN, INFN, Ciemat, IFIC, PoliAnnecy, HIT, OncoRay, IN2P3, Etoile, IBA)

24 September 2008 ENLIGHT, ESF Workshop-Oxford Manjit Dosanjh TERA INFN IFIC/CSIC IN2P3 OncoRay CERN PoliAnnecy Oxford IBA ICX Etoile GSI HIT PoliMilano Siemens Marburg BHTC MUVienna Ciemat TERA/CNAO/PoliMilano/UBern INFN IFIC-CSIC/Ciemat IN2P3/CEA? OncoRay CERN Oxford IBA ICX Etoile/ PoliAnnecy/Archade? GSI HIT/Marburg Siemens BHTC MUVienna FIRST LISTSECOND LIST

24 September 2008 ENLIGHT, ESF Workshop-Oxford Conclusions ENLIGHT++ continues to catalyse Common interdisciplinary environment Creation of maximum possible uniformity Inter-facilities uniformity and comparison Ease of exchange of information. Harmonization of data…………..

24 September 2008 ENLIGHT, ESF Workshop-Oxford Outlook Particle therapy will cover the full spectrum of radiotherapeutical indications One particle therapy facility for 10 million inhabitants Treatments will be fully accepted by the health insurance systems